Specialty Chemicals company Balaji Amines announced Q4FY23 & FY23 results:
- Consolidated Q4FY23:
- Revenue from Operations for Q4FY23 stood at Rs 476.90 crore, as compared to Rs 785.41 crore in Q4FY22. Total volumes stood at 26,505 MT for Q4FY23 as against 33,780 MT in Q4FY22.
- For Q4FY23,
- Amines volumes stood at 6,659 MT
- Amines Derivatives volumes stood at 8,607 MT
- Specialty Chemicals volumes stood at 11,239 MT
- EBITDA for Q4FY23 was Rs 98.63 crore, as compared to Rs 201.16 crore in Q4FY22. EBITDA margin for Q4FY23 stood at 20.68% as against 25.61% in Q4FY22. The fall in operating margin was primarily on account of degrowth in the pharma and API sector.
- PAT for Q4FY23 was Rs 55.21 crore, as compared to Rs 130.85 crore in Q4FY22. Diluted EPS for Q4FY23 stood at Rs 14.63 per equity share as against Rs 33.56 in Q4FY22.
- Consolidated FY23:
- Revenue from Operations for FY23 stood at Rs 2,370.64 crore, as compared to Rs 2,337.60 crore in FY22. Total volumes stood at 1,10,508 MT for FY23 as against 1,15,349 MT in FY22.
- For FY23,
- Amines volumes stood at 25,789 MT
- Amines Derivatives volumes stood at 33,091 MT
- Specialty Chemicals volumes stood at 51,628 MT
- EBITDA for FY23 was Rs 624.36 crore, as compared to Rs 637.39 crore in FY22. EBITDA margin for FY23 stood at 26.34% as against 27.27% in FY22. The fall in operating margin was primarily on account of degrowth in the pharma and API sector.
- PAT for FY23 was Rs 405.68 crore, as compared to Rs 417.90 crore in FY22. Diluted EPS for FY23 stood at Rs 100.47 per equity share as against Rs 113.71 in FY22.
On the performance, D. Ram Reddy, Managing Director, commented, "Despite headwinds in pharma API and Agro industries globally, we have delivered decent results. The fall in the margins was primarily on account of degrowth in Pharma API and Agro sector. We believe the performance of the company will improve gradually in the coming months, we anticipate a return to growth & margin levels similar to those achieved before the onset of the COVID-19 pandemic in due course, which we think is sustainable. In the past years, we experienced exceptionally high realizations for certain products, driven by global circumstances that have since normalized. Our capex that we had planned was based on the normalized profitability and hence our company will not be impacted adversely by it. In fact, we maintain a positive outlook on the sector and firmly believe in prioritizing growth. We are confident that the products we manufacture have significant demand within India and can effectively substitute imported alternatives. Revenues from the new commenced plants such as DMC, PG, Ethylamines will start contributing to our top line from coming quarters, which in turn can improve the margin profile of the company from Q1FY24.
In the long term we are confident of creating sustainable value for the stakeholders."